Day One Biopharmaceuticals Reports Strong Revenue Growth and Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2024
0mins
Should l Buy DAWN?
Source: Business Insider
Day One Biopharmaceuticals Inc shares surged by 25.62% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment.
The company reported a preliminary net product revenue of $155.4 million for 2025, marking a 172% year-over-year increase, driven by strong demand for its treatment OJEMDA™ for pediatric low-grade glioma. Additionally, the acquisition of Mersana for $25 per share is expected to enhance Day One's oncology pipeline, particularly with the innovative Emi-Le program targeting rare cancers, further solidifying its market position.
This impressive revenue growth and strategic acquisition position Day One favorably for future expansion, with projected revenues for 2026 expected to reach between $225 million and $250 million, indicating a strong commitment to developing new therapies and addressing unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DAWN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DAWN
Wall Street analysts forecast DAWN stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.530
Low
16.00
Averages
22.29
High
29.00
Current: 21.530
Low
16.00
Averages
22.29
High
29.00
About DAWN
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DAY ONE BIOPHARMACEUTICALS ANTICIPATES TOPLINE RESULTS FROM FIREFLY-2 CLINICAL TRIAL BY MID-2027
Clinical Trial Announcement: Day One Biopharmaceuticals has announced top-line data from its Firefly-2 clinical trial, which is expected to be released by mid-2027.
Focus on Pediatric Patients: The trial primarily targets pediatric patients, indicating a commitment to addressing unmet medical needs in this demographic.
See More
DAY ONE AND SERVIER FINISH ENROLLMENT IN KEY PHASE 3 FIREFLY-2 TRIAL OF TOVORAFENIB FOR FRONT-LINE TREATMENT OF PEDIATRIC LOW-GRADE GLIOMA (PLGG)
Enrollment Completion: Day One and Servier have completed enrollment for the Phase 3 trial of Tovorafenib, a treatment for pediatric low-grade glioma (PLGG).
Trial Focus: The trial aims to evaluate the efficacy and safety of Tovorafenib as a frontline treatment for children diagnosed with PLGG.
See More
Servier Completes Acquisition of Day One Biopharmaceuticals
- Acquisition Finalized: Servier has successfully acquired Day One Biopharmaceuticals at $21.50 per share, enhancing its leadership in low-grade glioma and solidifying its oncology market position.
- Strategic Advancement: This acquisition marks a significant step in Servier's ambition for 2030, particularly in treating pediatric low-grade gliomas, aiming to enhance support for patients with rare cancers.
- Portfolio Expansion: Day One's portfolio includes the FDA-approved OJEMDATM (tovorafenib), a treatment for the most common brain tumor in children, and its pipeline features several innovative drugs across various clinical stages.
- Integration of Scientific Capabilities: The scientific and clinical expertise of Day One will be integrated with Servier's resources to drive long-term innovation, ensuring effective treatment solutions for patients with rare cancers.
See More
Servier Completes Acquisition of Day One Biopharmaceuticals
- Acquisition Completed: Servier has successfully acquired all outstanding shares of Day One Biopharmaceuticals at $21.50 per share, which not only strengthens Servier's leadership in low-grade glioma but also expands its market share in oncology.
- Strategic Goal Advancement: Servier's President, Olivier Laureau, stated that this acquisition is a significant step towards their 2030 ambition to enhance their position in rare cancers, particularly in pediatric low-grade glioma.
- Portfolio Enhancement: Day One's portfolio includes the FDA-approved OJEMDATM (tovorafenib), which is already marketed in the U.S. and licensed to Ipsen outside the U.S., further enriching Servier's oncology product line.
- R&D Capability Improvement: The acquisition will integrate Day One's scientific and clinical capabilities, enhancing Servier's ability to develop innovative therapies aimed at providing meaningful treatments for children and families affected by rare cancers.
See More
Servier Completes Acquisition of Day One Biopharmaceuticals
- Acquisition Completed: Servier has successfully acquired all outstanding shares of Day One Biopharmaceuticals at $21.50 per share, which not only strengthens Servier's leadership in low-grade glioma but also expands its market share in oncology.
- Product and Pipeline Integration: The acquisition grants Servier access to the FDA-approved OJEMDATM, focusing on pediatric low-grade glioma, thereby enriching its oncology product line and enhancing clinical capabilities.
- Strategic Goal Advancement: Servier's President, Olivier Laureau, stated that this acquisition is a significant step towards achieving their 2030 ambition to strengthen their position in rare cancers, reflecting the company's commitment to innovation and patient needs.
- Combining Teams and Science: The scientific capabilities and team from Day One will merge with Servier's resources to drive innovation into tangible outcomes, aiming to provide better treatment options for patients with rare cancers.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Whitestone REIT (NYSE:WSR) for its sale to Ares Management Corporation at $19.00 per share, potentially violating fiduciary duties to shareholders and impacting their rights.
- Transaction Details: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is being sold to Merck for $53.00 per share in cash, with Halper Sadeh LLC suggesting that terms may limit superior competing offers, urging shareholders to be aware of their rights.
- Merger Impact: The merger of Rallybio Corporation (NASDAQ:RLYB) with Candid Therapeutics, Inc. is expected to result in Rallybio shareholders owning approximately 3.65% of the combined entity, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations aimed at securing additional rights for investors affected by securities fraud and corporate misconduct, highlighting their commitment to protecting investor interests.
See More
DAY ONE BIOPHARMACEUTICALS ANTICIPATES TOPLINE RESULTS FROM FIREFLY-2 CLINICAL TRIAL BY MID-2027
Clinical Trial Announcement: Day One Biopharmaceuticals has announced top-line data from its Firefly-2 clinical trial, which is expected to be released by mid-2027.
Focus on Pediatric Patients: The trial primarily targets pediatric patients, indicating a commitment to addressing unmet medical needs in this demographic.
See More
DAY ONE AND SERVIER FINISH ENROLLMENT IN KEY PHASE 3 FIREFLY-2 TRIAL OF TOVORAFENIB FOR FRONT-LINE TREATMENT OF PEDIATRIC LOW-GRADE GLIOMA (PLGG)
Enrollment Completion: Day One and Servier have completed enrollment for the Phase 3 trial of Tovorafenib, a treatment for pediatric low-grade glioma (PLGG).
Trial Focus: The trial aims to evaluate the efficacy and safety of Tovorafenib as a frontline treatment for children diagnosed with PLGG.
See More
Servier Completes Acquisition of Day One Biopharmaceuticals
- Acquisition Finalized: Servier has successfully acquired Day One Biopharmaceuticals at $21.50 per share, enhancing its leadership in low-grade glioma and solidifying its oncology market position.
- Strategic Advancement: This acquisition marks a significant step in Servier's ambition for 2030, particularly in treating pediatric low-grade gliomas, aiming to enhance support for patients with rare cancers.
- Portfolio Expansion: Day One's portfolio includes the FDA-approved OJEMDATM (tovorafenib), a treatment for the most common brain tumor in children, and its pipeline features several innovative drugs across various clinical stages.
- Integration of Scientific Capabilities: The scientific and clinical expertise of Day One will be integrated with Servier's resources to drive long-term innovation, ensuring effective treatment solutions for patients with rare cancers.
See More
Servier Completes Acquisition of Day One Biopharmaceuticals
- Acquisition Completed: Servier has successfully acquired all outstanding shares of Day One Biopharmaceuticals at $21.50 per share, which not only strengthens Servier's leadership in low-grade glioma but also expands its market share in oncology.
- Strategic Goal Advancement: Servier's President, Olivier Laureau, stated that this acquisition is a significant step towards their 2030 ambition to enhance their position in rare cancers, particularly in pediatric low-grade glioma.
- Portfolio Enhancement: Day One's portfolio includes the FDA-approved OJEMDATM (tovorafenib), which is already marketed in the U.S. and licensed to Ipsen outside the U.S., further enriching Servier's oncology product line.
- R&D Capability Improvement: The acquisition will integrate Day One's scientific and clinical capabilities, enhancing Servier's ability to develop innovative therapies aimed at providing meaningful treatments for children and families affected by rare cancers.
See More
Servier Completes Acquisition of Day One Biopharmaceuticals
- Acquisition Completed: Servier has successfully acquired all outstanding shares of Day One Biopharmaceuticals at $21.50 per share, which not only strengthens Servier's leadership in low-grade glioma but also expands its market share in oncology.
- Product and Pipeline Integration: The acquisition grants Servier access to the FDA-approved OJEMDATM, focusing on pediatric low-grade glioma, thereby enriching its oncology product line and enhancing clinical capabilities.
- Strategic Goal Advancement: Servier's President, Olivier Laureau, stated that this acquisition is a significant step towards achieving their 2030 ambition to strengthen their position in rare cancers, reflecting the company's commitment to innovation and patient needs.
- Combining Teams and Science: The scientific capabilities and team from Day One will merge with Servier's resources to drive innovation into tangible outcomes, aiming to provide better treatment options for patients with rare cancers.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Whitestone REIT (NYSE:WSR) for its sale to Ares Management Corporation at $19.00 per share, potentially violating fiduciary duties to shareholders and impacting their rights.
- Transaction Details: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is being sold to Merck for $53.00 per share in cash, with Halper Sadeh LLC suggesting that terms may limit superior competing offers, urging shareholders to be aware of their rights.
- Merger Impact: The merger of Rallybio Corporation (NASDAQ:RLYB) with Candid Therapeutics, Inc. is expected to result in Rallybio shareholders owning approximately 3.65% of the combined entity, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations aimed at securing additional rights for investors affected by securities fraud and corporate misconduct, highlighting their commitment to protecting investor interests.
See More
